|1.||Rosseel, M T: 1 article (11/2004)|
|2.||Vandewoude, K H: 1 article (11/2004)|
|3.||Buszman, Ewa: 1 article (11/2002)|
|4.||Bafeltowska, Jolanta J: 1 article (11/2002)|
|5.||Hawranek, Jadwiga: 1 article (11/2002)|
|6.||Mandat, Krzysztof: 1 article (11/2002)|
01/01/1989 - "A study of the pharmacokinetic parameters of cefotaxime (CTX) and desacetylcefotaxime (dCTX) in newborns was conducted; the former is commonly used for neonatal infections. "
04/09/1990 - "The unique interaction of cefotaxime with its active metabolite, desacetylcefotaxime, allows cefotaxime to be administered less frequently than three times a day in selected anaerobic infections. "
06/01/1984 - "Cefotaxime (CTX) and desacetylcefotaxime (des-CTX) alone and in combination were tested against anaerobic bacteria collected from clinical infections from several geographically diverse medical centers. "
|2.||Brain Abscess (Abscess, Brain)
12/01/1991 - "The aim of this investigation was to study the ability of cefotaxime and its active metabolite desacetylcefotaxime to penetrate into brain abscesses. "
12/01/1991 - "The brain abscess concentrations of cefotaxime and desacetylcefotaxime were 1.9 +/- 1.7 and 4.0 +/- 2.2 mg/liter, respectively. "
12/01/1991 - "Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans."
12/01/1991 - "Since both cefotaxime and desacetylcefotaxime penetrate well into the brain abscess, reaching concentrations above the MIC for probable bacteria except gram-negative anaerobes, it is concluded that cefotaxime in combination with metronidazole may be used as an alternative in the treatment of brain abscesses."
06/01/1987 - "Activity of six contemporary antibacterial agents against 96 isolates from purulent meningitis: the contribution of desacetylcefotaxime to antimicrobial potency."
12/01/1985 - "Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis."
12/01/1985 - "The pharmacokinetics and cerebrospinal fluid (CSF) penetration of cefotaxime (Ctx) and desacetylcefotaxime (dCtx) were evaluated in 13 infants and children with meningitis after dose 6 of Ctx in a multiple-dose intermittent intravenous infusion regimen (50 mg/kg every 6 h). "
09/01/1984 - "The MICs and MBCs of cefotaxime (CTX), desacetylcefotaxime (Des-CTX) and ceftriaxone (CTRX) were determined in relation to 4 of the principal bacterial species which cause meningitis, i.e., S. "
09/01/1984 - "[MICs and MBCs of cefotaxime, desacetylcefotaxime and ceftriaxone against four principal bacteria causing meningitis]."
|4.||Liver Diseases (Liver Disease)
07/01/1991 - "The dispositions of cefotaxime and its metabolite desacetylcefotaxime were investigated in patients with different forms of chronic parenchymal liver disease (CPLD). "
07/01/1991 - "Pharmacokinetics of cefotaxime and desacetylcefotaxime in patients with liver disease."
10/01/1983 - "Serum pools simulating specimens from healthy adults of both sexes, pregnant women, patients with liver disease, cardiac disease, or renal disease, and patients receiving gentamicin and tobramycin were supplemented with high and low concentrations of cefotaxime and desacetylcefotaxime. "
|5.||Body Weight (Weight, Body)
11/01/1987 - "The biliary elimination of cefotaxime (CTX) and its metabolite desacetylcefotaxime (DSCTX) were measured by HPLC in nine recently cholecystectomised patients following the i. v. injection of 15 mg/kg body weight of CTX. "
11/01/1987 - "The biliary excretion of cefotaxime (CTX) and its metabolite desacetylcefotaxime (DSCTX) was measured by HPLC in 9 recently cholecystectomized-patients following the IV injection of 15 mg/kg body weight of CTX. "
|5.||Cefoperazone (Cefoperazone Sodium)
|6.||Anti-Bacterial Agents (Antibiotics)